Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation

Nephrology Dialysis Transplantation

Volumn 14, Issue 11, 1999, Pages 2698-2703

  Saltissi, David ^a,c   Morgan, Colleen ^a   Westhuyzen, Justin ^b   Healy, Helen ^a  

^a Royal Brisbane and Keperra Hospitals ^*  (Australia)

^b Royal Brisbane Womens Hospital   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Anticoagulation; Haemodialysis; Heparin; Lipids; Low molecular weight heparins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CERTOPARIN; CHOLESTEROL; DALTEPARIN; DIGITALIS; ENOXAPARIN; FERRUM H; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; RECOMBINANT ERYTHROPOIETIN; TETRACYCLINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ARTIFICIAL KIDNEY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; CANNULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPRESSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FIBRIN FORMATION; HEMODIALYSIS; HUMAN; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOSIS; UREMIA;

EID: 0033281542     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.11.2698     Document Type: Article

References (24)

1. Effect of heparin and heparin fractions on platelet aggregation
2. Heparin-induced thrombocytopenia
3. The role of heparin in the changes of lipid patterns during a single hemodialysis
4. Heparin osteoporosis
5. Uremic bleeding: Clinical presentation and management
6. Spontaneous retroperitoneal hemorrhage in chronically hemodialyzed patients
7. Anticoagulant properties of heparin and heparin fractions
8. Low-molecular-weight heparin: Is small beautiful?
9. The new heparins
10. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin
11. Low molecular weight heparin-does it favourably affect lipid levels?
12. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration
13. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin
14. The effect of anticoagulation with low-molecular-weight heparin upon increased triglyceride and cholesterol concentrations in chronic hemodialysis patients
15. Low-molecular-weight heparin (LMWH): Influence on blood lipids in patients on chronic haemodialysis
16. Standard heparin (SM) versus 3 low-molecular-weight heparins (LMWH) in chronic dialysis
17. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients
18. Influence of various heparin preparations on lipoproteins in hemodialysis patients: A multicentre study
19. A low-molecular weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: Prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin
20. Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients
21. Low-molecular-weight heparin Fraxiparin in chronic hemodialysis. A dose-finding study
22. Optimisation de la dose d'énoxaparine (Lovenox®) dans la prevention de la coagulation des circuits d'hémodialyse: Résultats d'une étide multicentrique
23. Anticoagulacion en hemodialisis con dosis unica de heparina de bajo peso molecular
24. Longterm effects of low-molecular-weight heparin in hemodialyzed patients